LTX-315: complete guide

LTX-315, also called ruxotemitide or VP-315, is an investigational oncolytic peptide. This guide covers its structure, mechanism, trials, side effects and status.

Complete guide6 min read

Key takeaway

LTX-315 is a 9-mer cationic peptide with a molecular weight of 1,439.8 g/mol. In a Phase 1 trial of 39 patients with solid tumors, the most common related event was transient low blood pressure, in 46%. A 92-person Phase 2 study in basal cell carcinoma is complete, and it is not FDA-approved.

At a glance

Article typeComplete guide
Regulatory statusIn clinical trials“LTX-315 is not approved by the FDA for any use.” (this article)
ClassImmune & inflammation
Body systemsImmune system
Studies cited5 in this article · 5 across 1 article on LTX-315
Related productsBPC-157, TB-500 and thymic peptides

LTX-315 is a short, positively charged synthetic peptide designed to break open cancer cells and alert the immune system. It is now also called ruxotemitide and, in skin cancer work, VP-315. This guide covers its structure, mechanism, trials, reported side effects and status. Sources were checked on November 17, 2026.

Quick answer: LTX-315 is an investigational “oncolytic peptide” first developed by Lytix Biopharma. Lab and animal studies show it damages cell and mitochondrial membranes and triggers immunogenic cell death. Human trials have tested it in melanoma, sarcoma, basal cell carcinoma and other solid tumors. It has no FDA approval for any use.

Vitrapep does not sell LTX-315; this page is a reference summary of published research and regulatory information.

What is LTX-315?

LTX-315 is a synthetic peptide from Lytix Biopharma. Its developers describe a series of “chemically modified 9-mer cationic peptides,” and LTX-315 was the lead (Haug et al., 2016). A 9-mer is a chain of nine building blocks. Cationic means it carries a net positive charge.

The team states it was “de novo designed based on structure-activity relationship studies of host defense peptides” (Sveinbjørnsson et al., 2017). Host defense peptides are small natural molecules, such as LL-37, that help fight microbes. Our guide to types of peptides explains where this class fits.

PubChem files LTX-315 under the name ruxotemitide. It lists the formula as C78H106N18O9 and the molecular weight as 1,439.8 g/mol (PubChem CID 46200994). Verrica Pharmaceuticals calls it VP-315 (ruxotemitide, formerly LTX-315) under a worldwide license from Lytix (Verrica, 2026).

Table 1

LTX-315: key facts

Fact Detail
Structure type Synthetic cationic peptide, 9 building blocks, chemically modified
Class Oncolytic peptide (membrane-disrupting anticancer peptide)
Molecular formula C78H106N18O9
Molecular weight 1,439.8 g/mol
Development stage Phase 2 in basal cell carcinoma completed (2024); investigator-led Phase 2 in melanoma recruiting (started 2024)
Sponsor or developer Lytix Biopharma (originator); Verrica Pharmaceuticals (licensee for dermatology indications, as VP-315)

How does LTX-315 work?

LTX-315 acts on membranes. A 2016 lab study calls it “a cationic amphilytic peptide that preferentially permeabilizes mitochondrial membranes” (Zhou et al., 2016). Mitochondria are the energy-producing parts of a cell. Once they leak, the cell dies by a form of necrosis.

That death is “immunogenic.” The same study tested known warning signals: calreticulin moving to the cell surface, ATP release and HMGB1 leaving the nucleus. The authors reported that “LTX-315 induces all known ICD characteristics.” These data came from cultured cells and from treated tumors in animals.

A separate animal study found that LTX-315 reduced local regulatory T cells and myeloid-derived suppressor cells. In tumors resistant to CTLA4 blockade, it “cured the animals or caused tumor regressions with abscopal effects” (Yamazaki et al., 2016). An abscopal effect is shrinkage in tumors that were not treated. Our explainer on how peptides work covers receptor and membrane actions more broadly.

What is LTX-315 being studied for?

LTX-315 is not approved by the FDA for any use. ClinicalTrials.gov lists seven studies under its two names. Lytix sponsored early trials in patients with accessible solid tumors, starting with NCT01058616 in 2010. Conditions in the registered trials include:

  • advanced soft tissue sarcoma, combined with adoptive T-cell therapy (NCT03725605, Phase 2, completed 2021);
  • advanced melanoma, combined with pembrolizumab (NCT04796194, Phase 2, completed 2025);
  • resectable melanoma of stage III or higher, before surgery, with pembrolizumab (NCT06651151, NeoLIPA, recruiting); and
  • basal cell carcinoma, as VP-315 (NCT05188729, Phase 2, completed 2024).

Lytix describes NeoLIPA as an investigator-initiated Phase 2 study and lists it as currently recruiting (Lytix Biopharma, 2026). Oslo University Hospital is its registry sponsor.

What did the key trials show?

Phase 1 in solid tumors. This human trial enrolled 39 patients with advanced solid tumors. Its main goal was safety. Tumor volume fell by 30% or more in 29% of patients. The authors saw no partial responses by immune-related criteria. In biopsies, CD8+ T cells in the tumor increased in 12 of 14 samples (Spicer et al., 2021).

Phase 2 in basal cell carcinoma. Verrica ran an open-label, non-randomized, two-part study in 92 adults (NCT05188729). Its primary outcomes were safety measures, such as adverse events and skin reactions. The posted results show no participant stopped because of adverse events. Histologic clearance was a secondary outcome. We found no peer-reviewed paper with its results.

What side effects have studies reported?

The Phase 1 paper lists the most common treatment-related events. They were transient low blood pressure (46%), flushing (28%) and reactions where the peptide was given (38%). The most frequent grade 3 related event was hypersensitivity or anaphylaxis, in 4 patients (10%) (Spicer et al., 2021).

The basal cell carcinoma results on ClinicalTrials.gov list 92 participants at risk and no deaths. One participant had serious adverse events: atrial fibrillation, influenza and pneumonia. All 92 had other adverse events. The most frequent were local skin reactions at treated lesions: redness (86), hardening (81), tissue necrosis (74), swelling (67) and erosion (42). In Part 2, low blood pressure was the most frequent adverse event of special interest, in 4 participants.

What is LTX-315’s regulatory status, and how is it used in research?

LTX-315 is an investigational drug in the United States. We found no FDA marketing approval, and no FDA warning about it, in the sources we checked. In November 2026, Verrica said it is “exploring the potential of VP-315 to treat patients with Gorlin syndrome.” Verrica calls Gorlin syndrome a rare genetic disorder. It said it will update its business plan once any such study is finalized (Verrica, 2026).

In the lab, LTX-315 is a model compound for studying immunogenic cell death. The Zhou and Yamazaki papers above used it to measure danger signals and checkpoint-blockade synergy in cells and animals. Related membrane-active peptides include brilacidin.

Frequently asked questions about LTX-315

Is LTX-315 a peptide?

Yes. It is a chemically modified, positively charged peptide of nine building blocks, with a molecular weight of 1,439.8 g/mol.

Are LTX-315, VP-315 and ruxotemitide the same compound?

Yes. Verrica describes VP-315 as “ruxotemitide, formerly known as LTX-315 and VP-LTX-315.”

Is LTX-315 FDA-approved?

No. It has been tested only in clinical trials. No FDA approval was found.

What is an oncolytic peptide?

It is a peptide that kills cancer cells by breaking their membranes. With LTX-315, lab studies show the dying cells release signals that can draw in immune cells.

Who is developing LTX-315?

Lytix Biopharma created it and leads the melanoma work. Verrica Pharmaceuticals holds a license for dermatology indications, including basal cell carcinoma.

What to know now

  • Structure: 9-mer cationic synthetic peptide; C78H106N18O9; 1,439.8 g/mol.
  • Names: LTX-315, ruxotemitide, VP-315.
  • Mechanism: permeabilizes mitochondrial membranes and causes immunogenic cell death in lab and animal studies.
  • Evidence: Phase 1 in 39 patients; Phase 2 in 92 adults with basal cell carcinoma; melanoma Phase 2 recruiting.
  • Safety: transient low blood pressure, flushing, local skin reactions; hypersensitivity in 10% in Phase 1.
  • Status: investigational; not FDA-approved.

What we’re watching

Results from the NeoLIPA melanoma study (NCT06651151), with an estimated completion in May 2031. Verrica’s decision on a VP-315 study in Gorlin syndrome. A peer-reviewed paper on the Phase 2 basal cell carcinoma results. Related guides: LL-37 and brilacidin.

More for immune system

All 24 compounds for immune system

Sources: National Center for Biotechnology Information 2026, PubChem compound summary for CID 46200994, ruxotemitide; Haug 2016, Journal of Medicinal Chemistry, 59; Sveinbjørnsson 2017, Future Medicinal Chemistry, 9; Zhou 2016, Cell Death & Disease, 7; Yamazaki 2016, Cell Death & Differentiation, 23; Spicer 2021, Clinical Cancer Research, 27; Verrica Pharmaceuticals Inc 2022, Open-label proof of concept study of VP-315 in basal cell carcinoma; Oslo University Hospital 2024; Lytix Biopharma AS 2021, Intratumoral injection of LTX-315 in combination with pembrolizumab in advanced melanoma; Lytix Biopharma AS 2018, LTX-315 and adoptive T-cell therapy in advanced soft tissue sarcoma (ATLAS-IT-04); Lytix Biopharma AS 2010, Dose-escalation study of LTX-315 in patients with a transdermally accessible tumour; Verrica Pharmaceuticals 2026, Verrica Pharmaceuticals reports third quarter 2026 financial results; Lytix Biopharma 2026, Pipeline. All 13 citations

Back to the research library

References

  1. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 46200994, ruxotemitide. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/46200994
  2. Haug, B. E., et al. (2016). Discovery of a 9-mer cationic peptide (LTX-315) as a potential first in class oncolytic peptide. Journal of Medicinal Chemistry, 59(7), 2918-2927. https://doi.org/10.1021/acs.jmedchem.5b02025
  3. Sveinbjørnsson, B., et al. (2017). LTX-315: A first-in-class oncolytic peptide that reprograms the tumor microenvironment. Future Medicinal Chemistry, 9(12), 1339-1344. https://doi.org/10.4155/fmc-2017-0088
  4. Zhou, H., et al. (2016). The oncolytic peptide LTX-315 triggers immunogenic cell death. Cell Death & Disease, 7(3), e2134. https://doi.org/10.1038/cddis.2016.47
  5. Yamazaki, T., et al. (2016). The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade. Cell Death & Differentiation, 23(6), 1004-1015. https://doi.org/10.1038/cdd.2016.35
  6. Spicer, J., et al. (2021). Safety, antitumor activity, and T-cell responses in a dose-ranging phase I trial of the oncolytic peptide LTX-315 in patients with solid tumors. Clinical Cancer Research, 27(10), 2755-2763. https://doi.org/10.1158/1078-0432.CCR-20-3435
  7. Verrica Pharmaceuticals Inc. (2022). Open-label proof of concept study of VP-315 in basal cell carcinoma (ClinicalTrials.gov ID NCT05188729). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT05188729
  8. Oslo University Hospital. (2024). NeoLIPA: Neoadjuvant LTX-315 in combination with pembrolizumab in resectable stage III/IV melanoma (ClinicalTrials.gov ID NCT06651151). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT06651151
  9. Lytix Biopharma AS. (2021). Intratumoral injection of LTX-315 in combination with pembrolizumab in advanced melanoma (ClinicalTrials.gov ID NCT04796194). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT04796194
  10. Lytix Biopharma AS. (2018). LTX-315 and adoptive T-cell therapy in advanced soft tissue sarcoma (ATLAS-IT-04) (ClinicalTrials.gov ID NCT03725605). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT03725605
  11. Lytix Biopharma AS. (2010). Dose-escalation study of LTX-315 in patients with a transdermally accessible tumour (ClinicalTrials.gov ID NCT01058616). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT01058616
  12. Verrica Pharmaceuticals. (2026, November 12). Verrica Pharmaceuticals reports third quarter 2026 financial results [Press release]. https://verrica.com/press_release/verrica-pharmaceuticals-reports-third-quarter-2026-financial-results/
  13. Lytix Biopharma. (2026). Pipeline. Retrieved November 17, 2026, from https://www.lytixbiopharma.com/pipeline